Abstract
This review focuses on the current status of, and future directions for, pharmacogenetic research on nicotine dependence and smoking cessation treatment. Pharmacological treatment involving nicotine replacement therapy and bupropion for nicotine addiction and smoking cessation has been shown to be efficacious when provided in combination with behavioral support. Cessation rates remain somewhat modest, however, and one possibility is that success rates may be enhanced by offering treatments tailored to an individual's genotype. Nonetheless, research on this issue remains in its infancy, and although the scope for individualized treatment tailored to genotype is promising, there are substantial practical, ethical and social considerations that must be addressed before such research is translated into clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 211-223 |
| Number of pages | 13 |
| Journal | Pharmacogenomics |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 30 Apr 2005 |
Acknowledgements
This work was supported in part by Transdisciplinary Tobacco Use Research Center Grant P5084718 (CL), a UICC American Cancer Society International Fellowship for Beginning Investigators (MRM) and a grant from the Robert Wood John-son Foundation (AES).Funding
This work was supported in part by Transdisciplinary Tobacco Use Research Center Grant P5084718 (CL), a UICC American Cancer Society International Fellowship for Beginning Investigators (MRM) and a grant from the Robert Wood John-son Foundation (AES).
Keywords
- Bupropion
- Nicotine addiction
- Nicotine replacement therapy
- Smoking cessation
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmacology